Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04356937 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Tocilizumab on Patients With COVID-19
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 243
- Enrollment target
NCT04356937: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT04356937 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 243 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04356937, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 243 participants
- Enrollment target
Study Summary
This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation. The aim of this study is to test the effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection. Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures. Multi-organ dysfunction will be measured as the incidence of the following composite endpoint (mechanical ventilation, renal replacement therapy, mechanical support, need for inotropes or vasopressors, liver dysfunction (increased bilirubin), and all-cause mortality). We will also assess multiple pre-specified secondary (exploratory) endpoints and safety endpoints. We hypothesize that, as compared to placebo, tocilizumab will reduce transfer to the ICU, need for mechanical ventilation, increase rates of hospital discharge in patients diagnosed with severe COVID-19 infection and evidence of exaggerated inflammatory response.
Interventions
- DRUG Placebos
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2020-08-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04356937
The ClinicalTrials.gov registry entry for NCT04356937 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04356937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04356937 about?
NCT04356937 is a clinical study titled "Efficacy of Tocilizumab on Patients With COVID-19". This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation. The aim of this study is to test the effect of Tocilizumab on multi-organ ...
What is the current status of trial NCT04356937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 243 participants. The study started on 2020-04-20. Estimated completion is 2020-08-27.
What interventions are being tested in trial NCT04356937?
The interventions under investigation include: Placebos (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT04356937?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.